Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1529226

ESAT-6 protein suppresses allograft rejection by inducing CD4+Foxp3+ regulatory T cells through IkBa/cRel pathway

Provisionally accepted
Xiaofei Huang Xiaofei Huang 1Yuqun Zeng Yuqun Zeng 2Jingru Lin Jingru Lin 3Huazhen Liu Huazhen Liu 1Chunling Liang Chunling Liang 1Yuchao Chen Yuchao Chen 1Feifei Qiu Feifei Qiu 1Jonathan S Bromberg Jonathan S Bromberg 4Zhenhua Dai Zhenhua Dai 1*
  • 1 Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China
  • 2 Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China
  • 3 The Second Affiliated Hospital, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
  • 4 School of Medicine, University of Maryland, Baltimore, Maryland, United States

The final, formatted version of the article will be published soon.

    Maintenance immunosuppression is required after organ transplantation for suppression of alloimmunity or allograft rejection. However, continuous use of immunosuppressants may lead to various side effects, necessitating the use of alternative immunosuppressive drugs. The early secreted antigenic target of 6 kDa (ESAT-6) is a virulence factor and immunoregulatory protein of mycobacterium tuberculosis (Mtb), which alters host immunity through dually regulating development or activation of various immune cells. ESAT-6 may be a potential alternative immunosuppressant that could be utilized to suppress allograft rejection although it remains unknown whether ESAT-6 actually regulates alloimmunity. In this study, murine skin or heart allotransplantation was performed to determine the effects of ESAT-6 protein on allograft survival. Flow cytometric analyses were conducted to quantify CD4+Foxp3+ Tregs, while immunohistochemistry was carried out to observe allograft immunopathology. Western blotting was used to detect IĸBα/c-Rel signaling during Treg induction. Finally, CD4+CD25- conventional T cells were cultured to induce Tregs and their proliferation. Here we found that ESAT-6 significantly extended murine skin and heart allograft survival, alleviated CD3+ T cell infiltration and increased Foxp3+ Tregs in an allograft. ESAT-6 augmented the percentage of CD4+Foxp3+ Tregs, whereas it decreased the frequency of Th1 and CD4+/CD8+ effector T cells in spleen and lymph nodes (LNs) posttransplantation. ESAT-6 also induced CD4+Foxp3+ Tregs from CD4+CD25- T cells in vitro by activating IĸBα/c-Rel signaling pathway, whereas inhibition of c-Rel signaling blocked Treg induction. Moreover, it suppressed conventional CD4+CD25- T cell proliferation in vitro in the absence of antigen-presenting cells (APCs), with an increase in IL-10 and decrease in IFN-γ production. On the other hand, it did not significantly alter DC maturation after allotransplantation. Thus, ESAT-6 suppresses alloimmunity and inhibits allograft rejection by inducing CD4+Foxp3+ Tregs through IĸBα/c-Rel signaling pathway.

    Keywords: Transplantation, ESAT-6, Alloimmunity, Treg - regulatory T cell, Immunoregulation

    Received: 16 Nov 2024; Accepted: 20 Dec 2024.

    Copyright: © 2024 Huang, Zeng, Lin, Liu, Liang, Chen, Qiu, Bromberg and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zhenhua Dai, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.